bimekizumab
ucb pharmaceuticals
['axspa', 'be mobile 2', 'be mobile 1', 'bimekizumab', 'bemobile', 'consortium', 'be mobile']
dual il-17a/f inhibition with bimekizumab reduced mri inflammatory change in the sij and spine in axspa, and increasing proportion achieving mri remission at wk52, abst#pos0246 #eular2023 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Health,NASS Trustee, Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach